Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1176/ajp.145.10.1319a | DOI Listing |
BMJ Neurol Open
October 2024
Department of Neurology, Tsuchiura Kyodo General Hospital, Tsuchiura-shi, Ibaraki, Japan.
Eur J Pharm Biopharm
November 2024
International Pharmaceutical Federation (FIP), The Hague, Netherlands; St. Louis College of Pharmacy, University of Health Sciences and Pharmacy in St. Louis, MO, USA.
This publication is the first to report current, global, pediatric oral extemporaneous compounding practices. Complete survey responses were received from 479 participants actively involved in compounding across all the World Health Organization (WHO) regions. The survey addressed oral formulation of extemporaneous liquids, including the use of commercial or in-house vehicles, flavoring excipients, source of formulation recipes, and beyond use dates (BUDs).
View Article and Find Full Text PDFJ Acad Consult Liaison Psychiatry
June 2024
Neuropsychiatry Research and Education Group, Institute of Psychiatry, Psychology, and Neuroscience, London, United Kingdom; South London and Maudsley NHS Foundation Trust, London, United Kingdom.
Acute disturbance is a broad term referring to escalating behaviors secondary to a change in mental state, such as agitation, aggression, and violence. Available management options include de-escalation techniques and rapid tranquilization, mostly via parenteral formulations of medication. While the intramuscular route has been extensively studied in a range of clinical settings, the same cannot be said for intravenous (IV); this is despite potential benefits, including rapid absorption and complete bioavailability.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!